336 related articles for article (PubMed ID: 12798709)
1. Pre- and postmenopausal high-risk women undergoing screening for ovarian cancer: anxiety, risk perceptions, and quality of life.
Hensley ML; Robson ME; Kauff ND; Korytowsky B; Castiel M; Ostroff J; Hurley K; Hann LE; Colon J; Spriggs D
Gynecol Oncol; 2003 Jun; 89(3):440-6. PubMed ID: 12798709
[TBL] [Abstract][Full Text] [Related]
2. Three-dimensional ultrasonography and power Doppler in ovarian cancer screening of asymptomatic peri- and postmenopausal women.
Kurjak A; Prka M; Arenas JM; Sparac V; Merce LT; Corusic A; Ivancic-Kosuta M
Croat Med J; 2005 Oct; 46(5):757-64. PubMed ID: 16158468
[TBL] [Abstract][Full Text] [Related]
3. Serum CA 125 combined with transvaginal ultrasonography for ovarian cancer screening.
Roupa Z; Faros E; Raftopoulos V; Tzavelas G; Kotrotsiou E; Sotiropoulou P; Karanikola E; Skifta E; Ardavanis A
In Vivo; 2004; 18(6):831-6. PubMed ID: 15646829
[TBL] [Abstract][Full Text] [Related]
4. Large prospective study of ovarian cancer screening in high-risk women: CA125 cut-point defined by menopausal status.
Skates SJ; Mai P; Horick NK; Piedmonte M; Drescher CW; Isaacs C; Armstrong DK; Buys SS; Rodriguez GC; Horowitz IR; Berchuck A; Daly MB; Domchek S; Cohn DE; Van Le L; Schorge JO; Newland W; Davidson SA; Barnes M; Brewster W; Azodi M; Nerenstone S; Kauff ND; Fabian CJ; Sluss PM; Nayfield SG; Kasten CH; Finkelstein DM; Greene MH; Lu K
Cancer Prev Res (Phila); 2011 Sep; 4(9):1401-8. PubMed ID: 21893500
[TBL] [Abstract][Full Text] [Related]
5. Prophylactic Oophorectomy: Reducing the U.S. Death Rate from Epithelial Ovarian Cancer. A Continuing Debate.
Piver MS
Oncologist; 1996; 1(5):326-330. PubMed ID: 10388011
[TBL] [Abstract][Full Text] [Related]
6. Screening postmenopausal women for ovarian cancer: a systematic review.
Fung MF; Bryson P; Johnston M; Chambers A;
J Obstet Gynaecol Can; 2004 Aug; 26(8):717-28. PubMed ID: 15307976
[TBL] [Abstract][Full Text] [Related]
7. Psychological impact of screening for familial ovarian cancer.
Wardle FJ; Collins W; Pernet AL; Whitehead MI; Bourne TH; Campbell S
J Natl Cancer Inst; 1993 Apr; 85(8):653-7. PubMed ID: 8468723
[TBL] [Abstract][Full Text] [Related]
8. What happens after menopause? (WHAM): A prospective controlled study of depression and anxiety up to 12 months after premenopausal risk-reducing bilateral salpingo-oophorectomy.
Hickey M; Moss KM; Brand A; Wrede CD; Domchek SM; Meiser B; Mishra GD; Joffe H
Gynecol Oncol; 2021 May; 161(2):527-534. PubMed ID: 33583580
[TBL] [Abstract][Full Text] [Related]
9. Performance of ultrasound as a second line test to serum CA125 in ovarian cancer screening.
Menon U; Talaat A; Rosenthal AN; Macdonald ND; Jeyerajah AR; Skates SJ; Sibley K; Oram DH; Jacobs IJ
BJOG; 2014 Dec; 121 Suppl 7():35-9. PubMed ID: 25488086
[TBL] [Abstract][Full Text] [Related]
10. Screening for ovarian cancer: the preliminary experience of a familial ovarian cancer center.
Muto MG; Cramer DW; Brown DL; Welch WR; Harlow BL; Xu H; Brucks JP; Tsao SW; Berkowitz RS
Gynecol Oncol; 1993 Oct; 51(1):12-20. PubMed ID: 8244166
[TBL] [Abstract][Full Text] [Related]
11. Prospective study using the risk of ovarian cancer algorithm to screen for ovarian cancer.
Menon U; Skates SJ; Lewis S; Rosenthal AN; Rufford B; Sibley K; Macdonald N; Dawnay A; Jeyarajah A; Bast RC; Oram D; Jacobs IJ
J Clin Oncol; 2005 Nov; 23(31):7919-26. PubMed ID: 16258091
[TBL] [Abstract][Full Text] [Related]
12. Screening for ovarian cancer by transvaginal ultrasound and serum CA125 measurement in women with a familial predisposition: a prospective cohort study.
Bosse K; Rhiem K; Wappenschmidt B; Hellmich M; Madeja M; Ortmann M; Mallmann P; Schmutzler R
Gynecol Oncol; 2006 Dec; 103(3):1077-82. PubMed ID: 16904167
[TBL] [Abstract][Full Text] [Related]
13. Outcome of surveillance and prophylactic salpingo-oophorectomy in asymptomatic women at high risk for ovarian cancer.
Meeuwissen PA; Seynaeve C; Brekelmans CT; Meijers-Heijboer HJ; Klijn JG; Burger CW
Gynecol Oncol; 2005 May; 97(2):476-82. PubMed ID: 15863147
[TBL] [Abstract][Full Text] [Related]
14. CA125 and transvaginal ultrasound monitoring in high-risk women cannot prevent the diagnosis of advanced ovarian cancer.
Olivier RI; Lubsen-Brandsma MA; Verhoef S; van Beurden M
Gynecol Oncol; 2006 Jan; 100(1):20-6. PubMed ID: 16188302
[TBL] [Abstract][Full Text] [Related]
15. Tumor marker trends in asymptomatic women at risk for ovarian cancer: relevance for ovarian cancer screening.
Cane P; Azen C; Lopez E; Platt LD; Karlan BY
Gynecol Oncol; 1995 May; 57(2):240-5. PubMed ID: 7729742
[TBL] [Abstract][Full Text] [Related]
16. Results from an ultrasound-based familial ovarian cancer screening clinic: a 10-year observational study.
Tailor A; Bourne TH; Campbell S; Okokon E; Dew T; Collins WP
Ultrasound Obstet Gynecol; 2003 Apr; 21(4):378-85. PubMed ID: 12704748
[TBL] [Abstract][Full Text] [Related]
17. The efficacy of transvaginal sonographic screening in asymptomatic women at risk for ovarian cancer.
van Nagell JR; DePriest PD; Reedy MB; Gallion HH; Ueland FR; Pavlik EJ; Kryscio RJ
Gynecol Oncol; 2000 Jun; 77(3):350-6. PubMed ID: 10831341
[TBL] [Abstract][Full Text] [Related]
18. Differential blood count as triage tool in evaluation of pelvic masses.
Cramer DW; Benjamin Iv WJ; Vitonis AF; Berkowitz R; Goodman A; Matulonis U
Int J Gynecol Cancer; 2021 May; 31(5):733-743. PubMed ID: 32487682
[TBL] [Abstract][Full Text] [Related]
19. The role of ultrasound evaluation in the detection of early-stage epithelial ovarian cancer.
Fishman DA; Cohen L; Blank SV; Shulman L; Singh D; Bozorgi K; Tamura R; Timor-Tritsch I; Schwartz PE
Am J Obstet Gynecol; 2005 Apr; 192(4):1214-21; discussion 1221-2. PubMed ID: 15846205
[TBL] [Abstract][Full Text] [Related]
20. Performance of ultrasound as a second line test to serum CA125 in ovarian cancer screening.
Menon U; Talaat A; Rosenthal AN; Macdonald ND; Jeyerajah AR; Skates SJ; Sibley K; Oram DH; Jacobs IJ
BJOG; 2000 Feb; 107(2):165-9. PubMed ID: 10688498
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
